What is the role of Braftovi (encorafenib) and Mektovi (binimetinib) in combination for unresectable or metastatic melanoma?

This is a very timely question with the FDA approval of the encorafenib/binimetinib regimen. There are no randomized head-to-head trials comparing BRAF/MEK inhibitors so there are no clear data to guide which regimen is the most effective. The COLUMBUS trial reported the longest OS, PFS with the enc...